Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Dirithromycin 500 mg vs Dynabac 250 mg in Healthy Subjects
NCT02185846Phase 1Completed
- Sponsor
- Pharmaceutical Research Unit
- Start
- Jun 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dirithromycin in bacterial infection (2 arms), sponsored by Pharmaceutical Research Unit. Primary endpoints: Maximum Plasma Concentration Ratio at 120 hours and Area Under the Curve Ratio at 120 hours. Started Jun 2014; status: completed.
02
Drugs
dirithromycin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02185846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02185846.